Acetium family grows during September

Biohit Oyj Press Release August 26, 2015 at 9:30 a.m. local time (EEST)

Acetium product family grows with a new lozenge flavor. A consumer survey chose salty liquorice as the Finns’ favorite flavor. In the future, the package color will indicate the flavor. The new flavor will be in Finnish pharmacies during September.

Acetium lozenge effectively binds carcinogenic acetaldehyde (increases the risk of cancer) from saliva and forms a harmless compound that can be excreted from the body. The lozenge removes over 90 percent of the acetaldehyde dissolved into saliva during smoking and consumption of alcohol. The recommended dosage is 1 or 2 lozenges during smoking and drinking. CE marked Acetium lozenges are available in pharmacies throughout Finland.

Test your acetaldehyde exposure: http://www.acetium.com

CEO Semi Korpela, Biohit Oyj: ’Acetium lozenge Salty liquorice’s compound is identical with the existing lozenge of which it can be separated on the basis of the new package. The taste of salty liquorice is often perceived as pleasant and we believe it will increase the use of Acetium lozenge among health conscious consumers.’

Chief Medical Director Kari Syrjänen, Biohit Oyj: ‘The more people smoke and consume alcohol, the greater their acetaldehyde exposure and the risk of cancer. Over two million people are diagnosed with cancer of the upper gastrointestinal tract every year worldwide (see Additional information). A double-blind clinical trial is ongoing, assessing whether Acetium lozenge facilitates smoking quit. Research hypothesis is based on the ability of Acetium lozenge to eliminate acetaldehyde from tobacco smoke, which is known to increase nicotin dependence. (www.biohit.com, Study Protocols).’

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com